<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03174860</url>
  </required_header>
  <id_info>
    <org_study_id>CEBC-CU-2016-11-167</org_study_id>
    <nct_id>NCT03174860</nct_id>
  </id_info>
  <brief_title>Effect of Preoperative Diclofenac Potassium on Articaine Buccal Infitration Success</brief_title>
  <official_title>Effect of Preoperative Diclofenac Potassium on Articaine Buccal Infitration Success in Mandibular Molars With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of preoperative Diclofenac Potassium (50 mg
      Cataflam) on the anesthetic success of buccal infiltration with 4% articaine with epinephrine
      1:200,000 in mandibular molars with symptomatic irreversible pulpitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate the effectiveness of preoperative administration of Diclofenac
      Potassium (50 mg Cataflam) compared to placebo, one hour before treatment, on the anesthetic
      success of buccal infiltration with 4% articaine with epinephrine 1:200,000 in mandibular
      molars with symptomatic irreversible pulpitis. Patients with moderate-to-severe pre-operative
      pain are selected. Full medical and dental history will be obtained from all patients treated
      during this study by the operator. Clinical diagnosis of symptomatic irreversible pulpitis is
      to be confirmed. The primary outcome is success of buccal infiltration using articaine.The
      secondary outcomes are pain on injection. Patients will be recruited from the outpatient
      clinic of Endodontics at the Faculty of Oral and Dental Medicine, Cairo University.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients will be randomly divided into 2 groups:
Experimental group:
Diclofenac Potassium (50 mg, Cataflam) to be administered one hour before treatment.
Control group:
Placebo to be administered one hour before treatment.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of articaine buccal infiltration.</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Success of buccal infiltration using articaine. It will be measured using Heft-Parker visual analogue scale. The success will be considered if patient experienced no or mild pain (Heft-Parker VAS rating less than 54mm) while the failure will be considered if patient experience moderate-or-severe pain (Heft-parker VAS rating greater than 54mm) during access into dentin, access into pulp chamber or instrumentation of the canals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain on injection</measure>
    <time_frame>Intraoperative</time_frame>
    <description>The secondary outcome is pain on injection. It will be measured by Heft-Parker visual analogue scale during local anesthesia administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Pulpitis - Irreversible</condition>
  <condition>Anesthesia, Local</condition>
  <arm_group>
    <arm_group_label>Diclofenac Potassium 50mg tab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac Potassium 50mg (Cataflam) tablet to be administered one hour before treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to be administered one hour before treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Potassium 50mg Tab</intervention_name>
    <description>A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.</description>
    <arm_group_label>Diclofenac Potassium 50mg tab</arm_group_label>
    <other_name>Cataflam 50mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo will be taken one hour before initiation of endodontic treatment.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with active pain (moderate-to-severe) in mandibular molars.

          -  Patients with prolonged response to cold testing and electric pulp tester.

          -  Patient with the ability to understand and use pain scales.

          -  Patient with vital coronal pulp tissue on access.

          -  Patient who accept to enroll to the study.

        Exclusion Criteria:

          -  Patients' allergies or any other contraindication to diclofenac potassium or
             articaine.

          -  Pregnant and lactating females.

          -  Patients having pain medication in the last 6 hours.

          -  Patient has more than one symptomatic mandibular tooth in the same quadrant.

          -  Patients with periradicular pathosis and/or radiolucency other than widened
             periodontal ligaments.

          -  Patients with active peptic ulcer and gastrointestinal disorders.

          -  Patients with history of bleeding problems or anticoagulant use within the last month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amatallah H Al-Rawhani, Postgraduate</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Oral and Dental Medicine/ Cairo University.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Suzan AW Amin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Oral and Dental Medicine/ Cairo University.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shaima'a Gawdat, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Oral and Dental Medicine/ Cairo University.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amatallah H Al-Rawhani, Postgraduate</last_name>
    <phone>00201005275105</phone>
    <email>dr.amatallah@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr. Suzan A Amin, PhD</last_name>
    <email>swanees@rocketmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Dentistry</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+202 23634965</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Monteiro MR, Groppo FC, Haiter-Neto F, Volpato MC, Almeida JF. 4% articaine buccal infiltration versus 2% lidocaine inferior alveolar nerve block for emergency root canal treatment in mandibular molars with irreversible pulpits: a randomized clinical study. Int Endod J. 2015 Feb;48(2):145-52. doi: 10.1111/iej.12293. Epub 2014 May 22.</citation>
    <PMID>24702239</PMID>
  </reference>
  <reference>
    <citation>Prasanna N, Subbarao CV, Gutmann JL. The efficacy of pre-operative oral medication of lornoxicam and diclofenac potassium on the success of inferior alveolar nerve block in patients with irreversible pulpitis: a double-blind, randomised controlled clinical trial. Int Endod J. 2011 Apr;44(4):330-6.</citation>
    <PMID>21692235</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Amatallah Hussein Nasser Al-Rawhani</investigator_full_name>
    <investigator_title>Postgraduate Student in Endodontic Department/ Faculty of Oral and Dental Medicine/ Cairo University.</investigator_title>
  </responsible_party>
  <keyword>Pulpitis, irreversible Pulpitis, Hot tooth</keyword>
  <keyword>Cataflam, Diclofenac Potassium, Preoperative, Premedication, Analgesic</keyword>
  <keyword>Local anesthesia, Articaine, Buccal infiltration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulpitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Carticaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

